



GNE3130R1C1

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Ashkenazi et al.	)	Group Art Unit 1646
			)	
Appl. No.	:	10/002,796	)	
			)	
Filed	:	November 15, 2001	)	
			)	
For	:	SECRETED AND	)	
		TRANSMEMBRANE	)	
		POLYPEPTIDES AND NUCLEIC	)	
		ACIDS ENCODING THE SAME	)	
			)	
Examiner	:	OLGA N. CHERNYSHEV	)	
			)	

DECLARATION OF MARY GERRITSEN, Ph.D. UNDER 37 C.F.R. § 1.132

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Mary Gerritsen, Ph.D. declare and state that:

1. I am a co-inventor of the invention described in U.S. Patent Application Serial No. 10/002,796 entitled SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME.
2. My scientific Curriculum Vitae, including my list of publications, is attached to and forms part of this Declaration (Exhibit A).
3. From 1997-2001 I worked for Genentech as a Senior Scientist in the Department of Cardiovascular Research. During this time I directed and analyzed various bioassays and numerous molecular biology techniques including microarray analyses. In 2002, I accepted a position as Senior Director of Vascular Biology and Functional Genomics at Millennium Pharmaceuticals. Currently I am employed as the Senior Director of Molecular Pharmacology at Exelixis. These positions have provided me with extensive experience in vascular research, including angiogenesis and cancer development.

4. I am familiar with the specification and claims of U.S. Patent Application Serial No. 10/002,796, both the outstanding Office Action mailed August 24, 2004 and the first Office Action mailed April 27, 2004, and the issues raised therein.
5. The specification of U.S. Patent Application Serial No. 10/002,796 describes Assay 93 in Example 60. Assay 93 was performed to determine whether particular compounds are capable of inducing c-fos expression in pericyte cells. As stated in Example 60, the novel polypeptide PRO444 tested positive in this assay. The results and significance of Assay 93 are described in more detail herein in an effort to provide the U.S. Patent and Trademark Office (USPTO) with more information regarding the significance of c-fos induction in pericyte cells.
6. Assay 93 is an assay designed to determine whether particular compounds are capable of stimulating retinal pericytes through the c-fos pathway. Retinal pericytes are unique cells that play an important role in regulating angiogenesis. More specifically, pericytes help regulate capillary permeability and stabilize newly formed blood vessels. C-fos is a transcription factor involved in the regulation of cellular growth, including cancer and angiogenesis. Growth factors capable of stimulating pericytes signal through the c-fos pathway.
7. In light of their significant relationship with angiogenesis and cancer, it is useful to identify compounds capable of stimulating pericytes through the c-fos pathway in order to treat, promote and diagnose these conditions. Furthermore, one with skill in the art would reasonably conclude that the presence or overexpression of a compound capable of inducing c-fos expression in pericytes (e.g., PRO444) in a subject would more likely indicate the onset of cancer and/or angiogenesis as opposed to a subject who lacked this polypeptide. Likewise, a skilled artisan would also reasonably conclude that neutralizing compounds capable of stimulating c-fos expression in pericytes (e.g., PRO444) could be useful in preventing the onset and/or progression of cancer and/or angiogenesis.
8. In the outstanding Office Action, the Examiner alleged that with respect to the positive results observed when PRO444 was tested in Assay 93, "one skilled in the art would not attribute the induction of c-fos expression in pericytes by [PRO444] as a physiological reaction specifically induced by [PRO444]." (Office Action, page 4). On the contrary, Assay 93 included both positive and negative test controls: DME + 5% serum +/- PDGF and buffer respectively. The use of these controls ensured that the resulting data were attributed to the specifically tested compounds (e.g., PRO444), as opposed to some other factor or stimulus. Accordingly, a skilled artisan would readily have attributed the detected c-fos induction specifically to the PRO444 polypeptide.
9. In the first Office Action mailed April 27, 2004, the Examiner cited three journal articles: Janknecht et al., *Carcinogenesis*, vol. 16 no. 3, pp. 443-450 (1995), Herrera et al., *Progress in Neurobiology*, vol. 50, pp. 83-107 (1996), and Kovács, *Neurochem Int.* vol. 33, pp. 287-297 (1998) to support the assertion that c-fos induction is a "non-specific first line of cellular response" and that PRO444 accordingly lacks sufficient utility. It is important to note that none of these three articles discuss whether c-fos induction in

pericyte cells is a general response. For example Kovács is directed to c-fos induction in neuronal cells, and Herrera et al. is directed to c-fos expression in brain cells. Accordingly the teachings of these articles regarding c-fos induction are not necessarily applicable to pericytes, the specific cell type tested in Assay 93.

10. In Assay 93, 646 samples representing 382 different compounds were tested for their ability to induce c-fos expression in pericytes. The tested compounds included many known cytokines (e.g., Interleukin-1, tumor necrosis factor, interferon), growth factors (e.g., vascular endothelial growth factor, fibroblast growth factor, epidermal growth factor), chemokines, autocoids (e.g. endothelin), hormones (e.g. glucagons, luteinizing hormone) and polypeptides of unknown function. Of the 646 different samples that were assayed, only 48 tested positive for inducing c-fos expression in pericyte cells. Several of the 48 samples testing positive represented different lots of the same compound. As very few of the tested compounds were able to induce c-fos expression, it can be reasonably concluded from these results that the stimulation of c-fos in pericytes is not a generalized response.
11. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

January 21, 2005  
Mary Gerritsen, Ph.D.



**CURRICULUM VITAE**  
**Mary E. Gerritsen, Ph.D.**

**Residence**

**Address:** 541 Parrott Drive  
San Mateo Ca 94402  
Home phone 650 348 6492  
meg570@comcast.net

**Education:**

- 1975 Bachelor of Science  
University of Calgary  
Calgary, Alberta Canada  
Summa Cum Laude (Zoology)
- 1978 Doctor of Philosophy, Endocrinology/Pharmacology.  
University of Calgary, Faculty of Medicine.  
Calgary, Alberta Canada.

**Postdoctoral Training:**

- 1978-1980 Research Pharmacologist, Department of Pharmacology,  
University of California, San Diego.

**Academic Appointments:**

**Department of Physiology, New York Medical College**

- 1980-1986 Assistant Professor of Physiology
- 1986-1989 Associate Professor of Physiology.
- 1986 Associate Professor of Physiology with Tenure
- 1990-1996 Adjunct Associate Professor

**Pharmaceutical Industry Appointments:**

**Miles Pharmaceuticals (Renamed Bayer Corporation, April 1995)**

- 1990-1995 Senior Staff Scientist; Institute for Inflammation and Autoimmunity
- Led screening efforts for small molecule inhibitors of leukocyte adhesion inhibitors

- Identified flavonoids as potent inhibitors of cytokine induced gene expression
- Identified first synthetic inhibitors of IKB kinase, BAY 11-7082 and 11-7085.

1990-1992     Group Leader, Leukocyte Immigration.

- Coordinated screening efforts on MMP inhibitors for rheumatoid arthritis. Clinical candidate identified and developed for cancer metastasis
- Championed screen development for p38 MAP kinase. Program initiated and potent compounds identified
- Supervised group of four laboratories, (5 Ph.D.s and 9 Ras)
- Initiated reporter gene and transcription factor screens for inflammation targets
- Identified potent ICAM-1 blocking antibody
- Coordinated development of lipid mediator program. Developed screens for cyclooxygenase I and II inhibitors
- Worked with multidisciplinary teams including chemistry, pharmacokinetics, metabolism, formulation and pre-clinical development on inflammation projects-MMP inhibitors, p38 MAP kinase inhibitors, cytokine inhibitors, leukocyte adhesion inhibitors, cyclooxygenase inhibitors
- Evaluated in-licensing opportunities for small molecules in inflammation, osteoarthritis and osteoporosis

1992-1996     Arbeitskreis Moderator (Similar to Associate Director), Inflammation Research

- Coordination of all research discovery programs in Inflammation involving both internal and external research groups
- Supervised Six Arthritis Laboratories (8 Ph.d.s, 16-20 RAs)
- Presentation of research progress at quarterly in house meetings and at annual Bayer-wide meeting (held in Germany). Evaluation of other programs
- Evaluation of various in-licensing opportunities
- Wrote NDA for ketoprofen analog in-licensed by Bayer
- Recruited and built interdisciplinary group in Rheumatoid Arthritis and Chronic Inflammatory Disease
- Researched and wrote strategic plan and competitive assessment

1993-1997     Principal Staff Scientist, Inflammation Research

- Continued to support screening programs for NF- $\kappa$ B inhibitors
- Developed external collaborations with Vascular Research Division at Brigham and Womens Hospital-laboratories of Drs. Francis W. Luscinskas, Michael Gimbrone and Tucker Collins.

- Identified and mapped interaction of the coactivators CBP/p300 with NF- $\kappa$ B
- Led target validation team for Ceramide/Sphingomyelinase in Osteoarthritis

**Genentech Inc.**

1997- 2001

Senior Scientist, Department of Cardiovascular Research

- Initiated the development of an angiogenesis target discovery program using Curagen™ technology and Affymetrix oligonucleotide arrays
- Coordinated the screening efforts of multiple groups working on various aspects of vascular biology for SPDI (Secreted Protein Discovery Initiative)
- Evaluated various in-licensing opportunities for Cardiovascular Research, Oncology and Immunology
- Coordinated external collaboration with Dr. Alexander Clowes, University of Washington on EGF receptors and restenosis
- Served on preclinical development committee for VEGF-Therapeutic angiogenesis
- Served on Clinical Development committee for CD18 monoclonal antibody
- Identified critical roles for PECAM and VE-Cadherin in endothelial differentiation into tube-like structures
- Identified PPAR $\gamma$  ligands as potent inhibitors of growth factor induced angiogenesis
- Identified critical role of hepatocyte growth factor in endothelial differentiation in vitro and angiogenesis in vivo
- Demonstrated that KDR (VEGF receptor) plays essential role in endothelial cell differentiation into tube like structures
- Identified over 100 novel targets for either promotion or inhibition of angiogenesis
- Identified stanniocalcin as a novel angiogenic modulator
- Used affymetrix oligonucleotide arrays to identify critical angiogenesis progression factors in renal cell carcinoma
- Identified critical roles for matrix metalloproteinases and c-src in capillary lumen formation
- Identified a novel peptide fragment that may be a key player in inflammation and angiogenesis.

2000

Acting Director, Department of Cardiovascular Research

- Coordinated all department efforts in research discovery and preclinical development
- Continued to coordinate angiogenesis target discovery initiative. Discovered several novel molecules with key roles in endothelial differentiation in vitro, angiogenesis in vivo, and regulators of vascular permeability
- Evaluated various in-licensing opportunities
- Worked on Therapeutic Area Focus committee to define new directions for Cardiovascular Research
- Initiated a Cardiovascular Research Seminar series to bring in outside speakers on a biweekly basis. Coordinated collaborations that resulted from this initiative
- Head, Cardiovascular Recruitment committee. Organized successful search for Senior Scientist level positions.

2000-2001      Associate Director, Department of Cardiovascular Research, Genentech

- Researched and developed strategic plan for Department with Director
- Coordinated projects with internal and external research groups
- Provided scientific support to clinical and marketing groups
- Continued projects initiated above

2002-2003      Senior Director, Departments of Vascular Biology and Functional Genomics  
Millennium Pharmaceuticals, Inc. South San Francisco CA

- Served as project leader on three small molecular discovery programs at different stages-hit to lead, late development, high throughput screening
- Supervised vascular biology staff (four senior scientists, two post-doctoral fellows, 6 research associates, associate scientists and research investigators)
- Supervised histology core facility (one scientist and one research associate)
- Supervised functional genomics group at South San Francisco (two scientists at MSF), helped to coordinate activities with Millennium Cambridge facility.
- Developed strategic plan for vascular biology effort at Millennium
- Initiated large scale genomic screening program for targets in atherosclerosis, aortic aneurysm, and diabetic vascular disease as well as lung and renal fibrosis

- Initiated collaborations with over 10 academic laboratories in animal model development, human and primate disease models
- Served on pharmacology working group committee to oversee small molecule evaluation in vivo models
- Presented status updates to senior management at Scientific Review Committee meetings on a quarterly basis
- Coordinated MSF efforts in Bayer collaboration-Qualified Target initiative
- Developed and characterized animal models for drug screening programs.
- Worked on a biomarker initiative for each of our screening programs combining genomic analysis and mechanism of action studies.

2004-present Senior Director, Molecular Pharmacology. Exelixis South San Francisco, CA

- Supervise 4 associate directors (total group of 30)
- Direct all cell-based screens and pharmacodynamic studies to support projects in oncology, metabolic disease and inflammation
- Evaluate lead validation and lead optimization programs
- Establish outsourced pharmacology studies to support internal programs
- Identify new molecular targets for New Lead Discovery high through put screens

#### **Projects and Research Areas of Expertise:**

Eicosanoid Metabolism and Physiology

Adhesion Molecules

Mechanism of Drug Action

Matrix Metalloproteinases

Cell Based and Molecular Screening

Transcription Factors, Promoter Analysis

Endothelial Cell Biology, General Cell Biology

Vascular Biology

Microcirculation

Angiogenesis

Gene Expression Profiling using Differential Display, Affymetrix Arrays

Rosetta Resolver Software for microarray analysis

Functional Genomics

Rheumatoid Arthritis, Chronic Inflammatory Diseases

Atherosclerosis

Coronary, Peripheral and Cerebral Cardiovascular Disease



Macular Degeneration  
Diabetic retinopathy  
Models of fibrosis (lung, renal, liver)  
Cell based screening for oncology, metabolism and inflammation

**Awards and Honors:**

Province of Alberta Graduate Scholar 1976  
Medical Research Council Studentship 1976-1978  
Isaac Walton Killam Scholar and Merit Award 1977,1978  
Medical Research Council Fellow 1978-1980  
Alexander and Alexandrine Sinsheimer Scholar 1981, 1982  
Pharmacia Young Investigator Award, Microcirculatory Society 1983  
Mary Weideman Award, Microcirculatory Society 1984  
NIH Research Career Development Award 1987-1992  
Miles Science Award 1992  
Kurt Weiderhelm Award, Microcirculatory Society 1998  
Award named after me (Gerritsen Award), awarded annually by the Microcirculatory Society

**Major Committee Assignments**

**National and Regional:**

1985-	Ad hoc Grant Reviewer/Site Visitor: Experimental Cardiovascular Sciences Study Section (NIH)
1986-	Ad hoc reviewer VA Intramural Research Program
1987-	Ad hoc reviewer Medical Research Council of Canada, Canadian Heart Foundation, New York State Heart Association
1992-2001	Member, NIH Pathology A Study Section
1989-1992	Council, Microcirculatory Society
1991	Nominations Committee, Microcirculatory Society
1992	Chairperson, Publications Committee, Microcirculatory Society
1992	Liason Committee, American Physiology Society
1993	Steering Committee, North American Vascular Biology Organization

	Convenor, Blood Vessel Club, Anaheim CA
1994	Councillor, North American Vascular Biology Organization
1995	International Advisory Committee, 2nd Asian Microcirculation Meeting,
1996-	Co-Chairman, Keystone Symposia on Oxidant Stress, From Molecules to Man, Santa Fe NM
1997,1998,2001	Program Committee, Vascular Biology '98 and Vascular Biology '99, ATVB meeting 2001
2000	Vascular Biology Study Section, American Heart Association President, North American Vascular Biology Organization Development Committee, North American Vascular Biology Organization International Advisory Committee , World Congress of Microcirculation
2001	Coorganizer, with Richard Hynes and Denisa Wagner of Keystone Conference on Angiogenesis and Chronic Disease
2001	NIH Program Project Site Visit Team, National Cancer Institute
2001	NIH Stroke Progress Review Group
2001	External Scientific Advisory Committee, Institute for Medicine and Engineering, University of Pennsylvania
2002	Organized Career Symposium "Women in Industry" at the Exp. Biol.
2003-present	Development Committee Chair, North American Vascular Biology Organization

**New York Medical College:**

1980-1989	Member, Graduate Faculty (elected)	
1980-1985	Student Life Committee	
1980-1989	Safety Committee	
1980-1990	Member, Search Committees for Chairmen, Departments of	Cardi
1987-1989	Tenure and Promotions Committee	

**Bayer Corporation:**

1992	Co-Chairman, Bayer International Adhesion Meeting, Cologne Germany
1993-	Diversity Committee
1995-1996	Safety Committee

**Editorial Boards:**

1993-1998	Founding Editor and Editor in Chief, MICROCIRCULATION, the official journal of the Microcirculatory Society
1998-	Consulting Editor, MICROCIRCULATION
1999-	Editorial Board, ENDOTHELIUM, JOURNAL OF ENDOTHELIAL RESEARCH
1992-2000	Editorial Board, AMERICAN JOURNAL OF PHYSIOLOGY (Heart and Circulation)
1989-1995	Associate Editor, MICROVASCULAR RESEARCH
1993-2000	Editor, North American Vascular Biology Organization (NAVBO) Newsletter; Co-editor, NAVBO WWW Home Page
1995-present	Editorial Board, JOURNAL OF CARDIOVASCULAR PATHOLOGY
1996-2000	Editorial Board, CIRCULATION RESEARCH

**Memberships in Professional Societies:**

American Association for the Advancement of Science  
American Horticultural Society  
American Physiological Society  
American Society for Pharmacology and Experimental Therapeutics  
American Society for Research on Vision and Ophthalmology  
American Society for Investigational Pathology  
The Microcirculatory Society, Inc .  
North American Vascular Biology Organization (NAVBO)  
American Society for Cell Biology  
Society for Leukocyte Biology  
Peninsula Orchid Society  
American Orchid Society  
Pleurothallid Alliance

AHA Council on Arteriosclerosis, Thrombosis and Vascular Biology  
Fellow of the American Heart Association  
AHA Council on Stroke

**Summary of Teaching Experience:**

**A. Courses**

**University of Calgary:**

Pharmacology

Lecturer, Endocrinology 1977, 1978

**University of California, San Diego:**

Physiology/Pharmacology

Teaching Assistant and Laboratory Instructor 1979, 1980

(Pharmacokinetics, Metabolism labs)

**New York Medical College:**

Human Physiology

Lecturer (endocrinology) 1980-1990

Molecular Endocrinology

Course Director and Lecturer 1980-1990

Methods in Endocrinology

Course Director 1986

Cells of the Vessel Wall

Course Director 1986, 1988

Biochemical Pharmacology

Lecturer 1980-present (receptor pharmacology, cell culture, eicosanoid biochemistry, biologicals as drugs)

Review courses (Cardiovascular, Endocrinology) for Medical Boards at Bellvue Hospital, NY and other NY Medical College affiliate hospitals.

**Jefferson Medical College:**

Graduate Course in Human Physiology

Lecturer 1985-1987 (vascular cell biology, eicosanoid biochemistry)

**City College of New York**

Human Physiology

Lecturer 1980-1989 (Endocrinology)

**University of Virginia**

Shaking the Academic Tree: Alternative Careers 1999

## **B. Research Supervision**

Predoctoral research experiences (summers, elective periods): New York Medical College graduate and medical students  
Doctoral Research Advisor/Supervisor: New York Medical College Physiology, Pharmacology, Cell Biology  
Postdoctoral Supervisor: New York Medical College and Miles/Bayer Corporation  
Postdoctoral Supervisor: Genentech  
Summer Intern Advisor, Genentech

## **Sponsored Research Programs (Principal Investigator)**

### **National Institutes of Health**

1981-1984	NIH New Investigator Award "Cerebral Microvessels "
1985-1988	NIH HLBI RO1 Grant "Glucocorticoids and Microvessel Endothelium"
1985-1988	NIH EI RO1 Grant "Retinal Endothelial Cells"
1986-1989	Research Career Development Award (NIH, returned in 1990)
1990-1996	NIH HLBI RO1 grant "Glucocorticoids and Microvessel Endothelium"

### **Other Agencies**

1981-1984	American Heart Association Grant-in-Aid "Isolation and Characterization of Endothelial Cells from Cardiac Muscle"
1984	American Diabetes Association Grant-in-Aid "Effects of High Glucose on Retinal Microvascular Endothelial Cells"
1984-1986	Westchester Heart Association Grant-in-Aid " Effects of High Glucose on Cardiac Muscle Microvessel Endothelial Cells"
1984-1985	New York State Health Research Council Grant-in-Aid "Eicosanoid Metabolism in Cardiac Muscle Microvessel Endothelium"
1986	Boehringer Ingelheim Grant-In-Aid "Isolation of a Leukocyte Regulatory Factor from Microvessel Endothelium"
1990	Miles Inc. Grant in Aid. Fellowship support for Robert Mannix
1989	Fight for Sight Fellowship (sponsor for Julio Rimarachin)
1989	New York Eye and Ear Fellowship (sponsor for Julio Rimarachin)

## **Consultantships:**

1986-1989	INSITE VISION, Alameda California
1986-1989	Boehringer Ingelheim Pharmaceuticals, Ridgefield CT

2001	Department of Vascular Medicine, Stanford CA
2003-2004	Frazier HealthCare Ventures, Palo Alto, CA
2003	Xoma Corporation, Berkeley, CA
2004-	Macusight, Freemont, CA

**Students and fellows supervised and their current positions:**

1981-1985	Terry O Meyers, Ph.D. Associate Professor of Physiology, City University of New York
1985-1987	Robert Gundel, Ph.D. Vice President, Pre-clinical Research, Xoma Corporation
1984-1988	Anthony Capetandes, Ph.D. Scientist, Merck
1981-1983, 1987	Richard Rosenbaum, M.D. Fellow, Department of Cardiology, Jefferson Medical College, Philadelphia
1986-1989	Catherine Partridge, Ph.D. Associate Professor, Department of Biochemistry, Albany Medical College
1986-1989	Julio A. Rimarachin, M.D. Associate Professor, Cornell University Medical College
1985-1989	Robert Mannix, Ph.D. Research Cell Biologist, Children's Hospital, Harvard University
1988-1993	Tariq Moatter, Ph.D. Assistant Professor, Aga Khan University, Karachi Pakistan
1993-1999	Eric Schwartz, Ph.D. Post-doctoral fellow, Stanford University
1998	Jennifer Graham, Orthopedics resident, Brigham and Women's Hospital
1998-2000	Xiaohua Xin, Scientist, Eli Lilly
1999-present	Hainsworth Shin, Post-doctoral fellow, UCSD
2000-present	Max Tejada, Post-doctoral fellow, Genentech

## Bibliography

### Original Research Reports

1. **Gerritsen, M.E.** and Lederis K. Effects of urotensin I on intracellular levels of cAMP in the rat tail artery. *Eur. J. Pharmacol.* 60:211-219, 1979.
2. **Gerritsen, M.E.** and Lederis, K. Effects of urotensin I on the isolated rat tail artery. *Pharmacology.* 18:72-79, 1979.
3. **Gerritsen, M.E.**, Parks, T.P., Printz, M.P. Prostaglandin endoperoxide metabolism in bovine cerebral microvessels. *Biochim. Biophys. Acta* 619:196-206, 1980.
4. **Gerritsen, M.E.** and Printz, M.P. Prostaglandin E<sub>2</sub> synthesis in pigeon aorta: comparison of atherosclerosis-resistant (show racer) and atherosclerosis-prone (white carneau) pigeon breeds. *Artery* 8:56-62, 1980.
5. **Gerritsen, M.E.** and Printz, M.P. Sites of prostaglandin synthesis in the bovine heart and isolation of coronary microvessels. *Circ. Res.* 49:1159-1171, 1981.
6. **Gerritsen, M.E.** and Printz, M.P. PGD synthase in microvessels from the rat cerebral cortex. *Prostaglandins* 22:553-557, 1981.
7. **Gerritsen, M.E.**, Morgan, D.O.M., Parks, T.P., Printz, M.P. and Lederis, K. A proposed role for prostaglandins in the modulation of the relaxation response to urotensin I in isolated rat arteries. *Prostaglandins* 22:873-892, 1981.
8. **Gerritsen, M.E.** PGD<sub>2</sub> formation in the vasculature. Characteristics of rat tail vein PGH-PGD isomerase. *Prostaglandins* 25:105-120, 1983.
9. **Gerritsen, M.E.** and Cheli, C.D. Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit coronary microvessels and isolated cultivated coronary microvessel endothelial cells. *J. Clin. Invest.* 72:1658-1671, 1983.
10. Rodrigues, A.M. and **Gerritsen, M.E.** Release of 6-keto PGF<sub>1α</sub> and PGE<sub>2</sub> from isolated rabbit cerebral microvessels: effects of 100% O<sub>2</sub> room air and 95% N<sub>2</sub> 5% CO<sub>2</sub>. *Stroke* 15:717-722, 1984.
11. Levine, N., Tarlin, N. and **Gerritsen, M.E.** Effect of castration on prostaglandin mediated changes in membrane potential and prostaglandin synthesis in guinea pig seminal vesicles. *J. Reprod. Fertil.* 73:539-545, 1985.

12. Myers, T.O.M., Messina, E.J., Rodrigues, A.M. and **Gerritsen, M.E.** Altered prostaglandin synthesis in the cremaster muscle and aorta from streptozotocin-induced diabetic rats. *Am. J. Physiol.* 249:E374-379, 1985.
13. **Gerritsen, M.E.** and Burke, T. Insulin binding and effects of insulin on glucose metabolism and 2-deoxyglucose uptake in isolated rabbit coronary microvessel endothelial cells. *Proc. Soc. Exp. Biol Med.* 180:17-23, 1985.
14. Rosenbaum, R. and **Gerritsen, M.E.** Effects of dexamethasone on rabbit coronary microvessel endothelial (RCME) cell prostaglandin synthesis. *Am. J. Physiol.* 250:C970-977, 1986.
15. Allen, L.A. and **Gerritsen, M.E.** Regulation of hexose transport in cultured bovine retinal microvessel endothelium by insulin. *Exp. Eye Res.* 43:679-686, 1986.
16. **Gerritsen, M.E.**, Weinstein, B.I., Gordon, G.G. and Southren, A.L. Prostaglandin synthesis and release from cultured human trabecular meshwork cells and scleral fibroblasts. *Exp Eye Res.* 43:1089-1102, 1987.
17. **Gerritsen, M.E.**, Ngnalene, D.M. and Rodrigues, A.M. Calcium ionophore (A23187) and arachidonic acid stimulated prostaglandin release from microvascular endothelial cells: effects of calcium antagonists and calmodulin inhibitors. *J. Pharm. Exp. Ther.* 240:837-846, 1987.
18. Belloni, F.L., Liang, B.C. and **Gerritsen, M.E.** Effects of alkylxanthines and calcium antagonists on adenosine uptake by cultured rabbit coronary microvessel endothelium. *Pharmacol.* 35:1-15, 1985.
19. Churchill, L., Buasback, H., **Gerritsen, M.E.** and Ward, P.E. Metabolism of opoid peptides by cerebral microvasculature aminopeptidase. *Biochim. Biophys. Acta* 923:35-41, 1987.
20. **Gerritsen, M.E.** Eicosanoid production by the coronary microvascular endothelium. *Fed. Proc.* 46:47-53, 1987.
21. **Gerritsen, M.E.** Functional heterogeneity of vascular endothelium. *Biochemical Pharmacology.* 36:2701-2711, 1987.
22. Gundel, R.H., **Gerritsen, M.E.**, Gleich, G.J. and Wegner, C.D. Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. *J. Appl. Physiol* 68:779-786, 1990.
23. **Gerritsen, M.E.**, Burke, T. and Allen, L. Glucose starvation is required for insulin stimulation of hexose uptake and metabolism in coronary microvascular endothelial cells. *Microvascular Research* 35:153-166, 1988.



24. Gundel, R.H., **Gerritsen, M.E.**, and Wegner, C.D. Antigen coated sepharose beads induce airway eosinophilia and airway hyperresponsiveness in cynomologous monkeys. *Am. J. Resp. Dis.* 140:629-633, 1989.
25. Medow, M.E., Intrieri, L., Moatter, T. and **Gerritsen, M.E.** Dexamethasone effects on membrane lipid composition of microvascular endothelial cells. *Am. J. Physiol.* 257:C512-519, 1989.
26. Partridge, C.A., **Gerritsen, M.E.**, Southren, A.L. and Weinstein, B.I. Dexamethasone induces specific proteins in human trabecular meshwork cells. *Invest. Ophthalmol. Vis. Sci.* 30:1843-1847, 1989.
27. **Gerritsen, M.E.**, Rimarachin, J., Perry, C.A. and Weinstein, B.I. Arachidonic acid metabolism by cultured bovine corneal endothelial cells. *Invest. Ophthalmol. Vis. Sci.* 30:698-705, 1989.
28. **Gerritsen, M.E.**, Perry, C.A. Moatter, T. Cragoe, E.J.jr and Medow, M.S. Role of  $\text{Na}^+/\text{H}^+$  antiport in agonist specific prostaglandin release from microvessel endothelium. *Am. J. Physiol.* 256:C831-839, 1989.
29. Partridge, C.A. and **Gerritsen, M.E.** Dexamethasone increases the release of three 44 kD proteins immunologically related to plasminogen activator-inhibitor-1 from HUVE and RCME cells. *Thromb. Res.* 57:139-154, 1990.
30. Capetandes, A. and **Gerritsen, M.E.** Simplified methods for the selective and consistent culture of bovine retinal endothelial cells and pericytes. *Invest. Ophthalmol. Vis. Sci.* 31:1738-1744, 1990.
31. **Gerritsen, M.E.** and Perry, C.A. Regulation of eicosanoid synthesis in microvessel endothelium: glucocorticoids do not effect arachidonoyl CoA synthase activity. *Biochim. Biophys. Acta* 1045:174-179, 1990.
32. Masferrer, J.L., Rimarachin, J.A., **Gerritsen, M.E.**, Falck, J.R., Yadagiri, P., Dunn, M.W. and Lanaiido-Schwartzman, M.. 12 (R) hydroxyeicosatrienoic acid, a potent chemotactic and angiogenic factor produced by the cornea. *Exp. Eye Res.* 52:417-424, 1991.
33. **Gerritsen, M.E.**, Schwarz, S.M., and Medow, M.S. Glucocorticoid-mediated alterations in fluidity of rabbit cardiac muscle microvessel endothelial cell membranes: Influences on eicosanoid release. *Biochim. Biophys. Acta* 1065:63-68, 1991.
34. Koller A., Sayedi, N, **Gerritsen, M.E.** and Kaley G. EDRF release from microvascular endothelial cells dilates arterioles *in vivo*. *Am. J. Physiol.* 261:H128-H133, 1991.

35. Moatter T and **Gerritsen, M.E.** Fibroblast growth factor upregulates PGG/H synthase in rabbit microvascular endothelial cells by a glucocorticoid independent mechanism. *J. Cell. Physiol.* 151:571-578, 1992.
36. Gundel, R.H., **Gerritsen, M.E.**, and Wegner, C.D. Polymyxin B-induced bronchial neutrophilia does not alter airway responsiveness to methacholine in cynomologous monkeys. *Clin. Exp. Allergy* 22:357-363, 1992.
37. Carley, W.W., Niedbala, M.J. and **Gerritsen, M.E.** Isolation and partial characterization of human lung microvessel endothelial cells. *Am. J. Resp. Cell. Mol. Biol.* 7:620-630. 1992.
38. **Gerritsen, M.E.** and Bloor, C. Endothelial gene regulation in response to injury. *FASEB. J.* 7:523-532, 1993.
39. Nishida, M., Carley, W.W., **Gerritsen, M.E.**, Ellingsen, O., Kelley, R. and Smith, T.W. Isolation and characterization of human and rat cardiac microvascular endothelial cells and co-culture with adult rat ventricular myocytes. *Am. J. Physiol.* 264:H639-H652, 1993.
40. **Gerritsen, M.E.**, Szczepanski, A., Perry, C.A., Shen, C.P. Kelley, K.A., Ligon, G. and Carley, W.W. Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured human endothelial cells derived from rheumatoid synovium. *Arth. Rheum* 36:593-602, 1993.
41. Mannix, R.J., Kelley, K.A. and **Gerritsen, M.E.** A novel nucleotide receptor in rabbit microvascular endothelial cells. *Am. J. Physiology* 265:H675-680, 1993.
42. Acevedo, A.D., Bowser, S., **Gerritsen, M.E.** and Bizios, R. Morphological and proliferative responses of endothelial cells to hydrostatic pressure: role of fibroblast growth factor *J. Cell. Physiol.* 157:603-614, 1993
43. **Gerritsen, M.E.**, Niedbala M.J. and Carley, W.W. Cytokine regulation of microvascular endothelial cells. *Blood Cells* 19:325-342, 1993.
44. Szczepanski, A., Moatter, T.M., Carley, W.W. and **Gerritsen, M.E.** Induction of cyclooxygenase II in human synovial microvessel endothelial cells by IL-1. Inhibition by glucocorticoids *Arth. Rheum.* 37:495-503, 1994.
45. Kauffmann, D.J.H., van Meurs, J.C., Mertens, D.A.E., Peperkamp, E. and **Gerritsen, M.E.** IL-6 is elevated in vitreous of patients with proliferative vitreoretinopathy. *Invest Ophthal Vis Sci.* Vol 35:900-906, 1994.
46. Brown, Z., **Gerritsen M.E.**, Carley W.W., Streiter, R., Kunkel S.L., and Westwick J. Cytokine regulation of IL-8 and MCP-1 synthesis and release in human lung microvessel endothelium. *Am J. Pathol.* 145:913-921, 1994.

47. Moatter, T. and **Gerritsen, M.E.** FGF upregulates cyclooxygenase II in microvessel endothelium: role of protein kinase C. *Microcirculation* 1:79-88, 1994.
48. Shen, C.P. Ranges, G., Moatter, T., Ligon, G.F., Huwiler, K. Phan, S., Carley, W.W. and **Gerritsen, M.E.** Role of the p55 and p75 TNF receptors in the upregulation of ICAM-1 expression in synovial microvascular endothelium and synergistic actions of interferon gamma
49. **Gerritsen, M.E.**, Shen C.P., McHugh, M., Atkinson W.C., Kiely J., Milstone D., Luscinskas F.W. and Gimbrone M.A. Jr. Activation-dependent isolation and culture of murine pulmonary microvascular endothelium. *Microcirculation* 2: 151-163, 1995.
50. **Gerritsen M.E.**, Carley W.W., Ranges G.E., Shen C.P., Phan S.A. Ligon G.F. and Perry C.A. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. *Am J Pathol* 147:1-15, 1995.
51. Abraham N.G., Lavrovsky, Y., Schwartzman M.L., Stoltz R.A., Levere, R.D., **Gerritsen M.E.**, Shibahara S and Kappas A. Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity. *Proc Natl Acad Sci (USA)* 92: 6797-6802, 1995
52. Stolz R.A., Conner M.S., **Gerritsen M.E.**, Abraham N.G., and Lanaiido-Schwartzman M. Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal derived eicosanoid. *Am J Pathol.* 148:129-139, 1996.
53. Kalfa T.A., **Gerritsen M.E.**, Carlson E.C., Binstock A.J., and Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. *Invest Ophthalmol Vis Sci* 36:2358-2367, 1996.
54. Chilian W.M., Bassingthwaighte J.B., Curry F.R., Cannon R.O., Davis M.J., Dellsperger K.C., Duling B.R., Fuster V., **Gerritsen M.E.**, Hoffman J.I.E., Kajiya F., Ku D.D., Lamping K.G., Laughlin H., Taylor A., and Small A.E.. The Coronary Microcirculation in Health and Disease. A NIH Workshop on the Coronary Circulation. *Circulation* 95:522-528, 1997.
55. Gundel R., Lindell D., Harris P., Fournel M., Jesmok G. and **Gerritsen M.E.** IL-4 induced leukocyte trafficking in cynomologous monkeys. Correlation with expression of adhesion molecules and chemokine generation *Clin Exp Allergy* 26:719-729, 1996.
56. Hoyt D.G., Mannix R.J., **Gerritsen M.E.**, Watkins S.A., Lazo J.S. and Pitt B.R. Integrins inhibit LPS-induced DNA strand breakage in cultured lung endothelial cells. *Am J Physiol* 14:L689-L694, 1996.
57. **Gerritsen, M.E.** Physiological and pathophysiological roles of eicosanoids in the microcirculation *Cardiovascular Res.* 32:720-732, 1996

58. Luscinskas, F.W. Ding H., Tan P., Cumming D., Tedder T.F. and **Gerritsen M.E.** L-selectin preferentially mediates monocyte attachment and rolling on TNF $\alpha$  activated vascular endothelium under flow in vitro. *J. Immunol.* 156:326-335, 1996
59. Medow M.S., Kletter L.B. and **Gerritsen M.E.** Glucocorticoid induced alterations in membrane fluidity: Evidence for membrane stabilizing effects mediated by glucocorticoid induced modifications of membrane lipid composition (submitted for publication)
60. Read, M., Neish A.S., **Gerritsen M.E.**, and Collins T. Nuclear I $\kappa$ B $\alpha$  and the post-induction transcriptional repression of E-selectin and VCAM-1. *J. Immunol.* 157: 3472-3479, 1996
61. Panes, J., **Gerritsen, M.E.**, Anderson D.C., Miyasaka M. and Granger DN. Apigenin inhibits TNF-induced ICAM-1 upregulation in vivo. *Microcirculation* 3: 279-286, 1996
62. Carley W.W., Szczepanski A. and **Gerritsen M.E.** Human synovial endothelial cells co-express cytokeratins and hyaluronic acid: regulation of hyaluronic acid production by cytokines and fibroblast growth factor. *Microcirculation* 3: 359-370, 1996.
63. **Gerritsen M.E.**, Padgett R., Atkinson W.C., Gimbrone M.A. Jr, and Milstone, D. Endothelial cells from E-selectin deficient mice form tubes in vitro *Lab. Invest.* 175-184, 1996.
64. Schwartz, E., Bizios, R. Moatter, T. and **Gerritsen, M.E.** Endothelial gene regulation in response to hydrostatic pressure. (submitted for publication)
65. Barkalow F.J., Goodman M.J., **Gerritsen M.E.** and Mayadas T.N. Importance of P-selectin for neutrophil adhesion to microvascular endothelial cells of the brain. *Blood.* 88: 4585-4593, 1996.
66. **Gerritsen, M.E.**, Williams, A.J., Neish, A.S., Moore, S., Shi, Y and Collins, T. CBP/p300 are transcriptional coactivators of p65. *Proc Natl Acad Sci U S A* 94:2927-2932, 1997
67. Allport, J.R., Ding, H., Collins, T., Vestweber, D., **Gerritsen, M.E.** and Luscinskas, F.S. Endothelial-dependent mechanisms regulate leukocyte transmigration: a process involving the proteasome and disruption of the VE-Cadherin complex at endothelial junctions. *J Exp Med* 186:517-527, 1997
68. Henninger, D.D., Panes, J., Russel, J., **Gerritsen, M.E.**, Anderson, D.C. and Granger, D.N. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. *J Immunol.* 158: 1825-1832, 1997
69. Pierce, J.W., Schoenleber, R., Jesmok, G., Best, J., Moore, S.A., Collins, T. and **Gerritsen, M.E.** Novel inhibitors of cytokine-induced I $\kappa$ B $\alpha$  phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. *J Biol Chem*; 272 : 21096-21103, 1997

70. Schwartz, E.A., Bizios, R., Medow, M.S., **Gerritsen, M.E.** Exposure of human vascular endothelial cells to sustained hydrostatic pressure stimulates proliferation. Involvement of the  $\alpha_v$  integrins. *Circ. Res.* 84:315-322, 1999.
71. Komatsu, S., Flores, S., **Gerritsen, M.E.**, Anderson, D.C. and Granger, D.N. Differential upregulation of circulating soluble and membrane-bound forms of intercellular adhesion molecule-1. *Am J Pathol* 151:205-214, 1997.
72. Horie Y., Chervenak R.P., Wolf R., **Gerritsen M.E.**, Anderson D.C., Komatsu S., Granger D.N. Lymphocytes mediate TNF-alpha-induced endothelial cell adhesion molecule expression: studies on SCID and RAG-1 mutant mice. *J. Immunol* 159: 5053-5062, 1997
73. Hoyt D.G., Rizzo M., **Gerritsen M.E.** Pitt B.R., Lazo J.S. Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin. *Am J Physiol* 273: L612-L617, 1997.
74. Henninger D.D., **Gerritsen M.E.**, Granger D.N. Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. *Circ Res* 81:274-281, 1997.
75. **Gerritsen M.E.**, Shen C.P., Perry C.A. Synovial fibroblasts and the sphingomyelinase pathway: sphingomyelin turnover and ceramide generation are not signaling mechanisms for the actions of tumor necrosis factor-alpha. *Am J Pathol* 152:505-512, 1998.
76. Carley, W., Ligon, G., Phan, S., Dzuiba, J., Kelley, K., Perry, C.A. and **Gerritsen, M.E.** Distinct ICAM-1 forms and expression pathways in synovial microvascular endothelial cells. *Cellular and Molecular Biology* 45:79-88, 1999.
77. Sheppard, K.A., Phelps, K.M., Williams, A.J., Thanos, D., Glass, C.K., **Gerritsen, M.E.** and Collins, T. Nuclear integration of glucocorticoid receptor and NF-KB signaling by CREB binding protein and steroid receptor coactivator-1. *J. Biol. Chem.* 273:29291-29294, 1998.
78. Langley, R.R., Russell, J., **Gerritsen, M.E.**, Specion, R.D. and Granger, D.N. Quantification of murine endothelial cell adhesion molecules in solid tumors. *Am J. Physiol* 277:H1156-66, 1999.
79. Mori, N., Horie, Y., **Gerritsen, M.E.** and Granger D.N. Ischemia-reperfusion induced microvascular responses in LDL-receptor -/- mice. *Am J Physiol* 276:H1647-H165, 1999.
80. Yang, S., Graham, J., Kahn, J., Schwartz, E.A. and **Gerritsen, M.E.** Differential roles for CD31 and VE-cadherin in formation of vascular tubes and lumens in three-dimensional gels. *Am J. Pathol* 155:887-95, 1999.

81. Mori, N., Horie, Y., **Gerritsen, M.E.**, Anderson, D.C.. and Granger, D.N. Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds. *Gut* 33:186-195, 1999.
82. Xin, X., Yang, S., Kahn, J., Kowalski, J. and **Gerritsen, M.E.** Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) ligands are potent inhibitors of angiogenesis in vitro and in vivo. *J. Biol. Chem.* 274:9116-9121, 1999.
83. Eppihimer, M.J., Russell, J., Langley, R., **Gerritsen, M.**, Granger D.N. Role of tumor necrosis factor and interferon gamma in endotoxin-induced E-selectin expression. *Shock* 11:93-7, 1999.
84. Kahn, J., Mehraban, F., Ingle, G., Xin, X., Bryant, J.E., Vehar G., Schoenfeld J., Grimaldi C.J., Peale F., Draksharapu A., Lewin D.A., **Gerritsen M.E.**. Gene expression profiling in an in vitro model of angiogenesis. *Am J Pathol* 156:1887-900, 2000.
85. Li, B., Fuh, G., Meng, G., Xin, X., **Gerritsen, M.E.**, Cunningham, B., de Vos, A. Receptor-selective variants of human VEGF: generation and characterization . *J. Biol. Chem.* 275(38):29823-8, 2000.
86. Peale, F.. and **Gerritsen, M.E.** Gene expression analysis in angiogenesis and vascular development. *J. Pathol.* 195:7-19, 2001.
87. Xin, X., Yang, Y., Ingle, G., Zlot, C., Rangell, L., Kowalski, J. Schwall, R., Ferrara, N., and **Gerritsen, M.E.** Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo *Am J. Pathol* 158:1111-1120, 2000
88. Langley RR, Carlisle R, Ma L, Specian RD, **Gerritsen M.E.**, Granger DN. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. *Microcirculation* 8:335-345, 2001.
89. Yang, S., Xin, X., Zlot, C., Ingle, G., Fuh, G., Li, B., Moffat, B., de Vos, A., and **Gerritsen, M.E.** Vascular Endothelial Cell Growth Factor-Driven Endothelial Tube Formation Is Mediated by Vascular Endothelial Cell Growth Factor Receptor-2, a Kinase Insert Domain-Containing Receptor .*Arterioscler Thromb Vasc Biol* 21:1934-1940, 2001
90. Shin, H. Bizios, R and **Gerritsen, M.E.**. Cyclic pressure modulates endothelial cell proliferation and apoptosis. *Biomed. Eng.* 30:. 296-304
91. Kiosses, W.B., Hood, J., Yang, S., **Gerritsen, M.E.**, Cheresch, D.A, Alderson, N. and Schwartz, M.A.. A dominant negative p65 PAK peptide inhibits angiogenesis. *Circ, Res.* 90:697-702,, 2002
92. Schwartz, E.A., Shin, H., Bizios, R. and **Gerritsen, M.E.**. Role of the FGF receptor bek in hydrostatic pressure induced endothelial cell proliferation (submitted).

93. **Gerritsen, M.E.** Angiogenesis and Chronic Disease. Trends in Molecular Medicine 7: 333-334, 2001
94. **Gerritsen, M.E.**, Soriano, R., Zlot, C., Yang, S., Ingle, G., Toy, K., Peale, F., Wu, T. and Williams, P.M. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling set. Physiological Genomics 10:13-20, 2002
95. Shin, H. , Bizios, R., and **Gerritsen, M.E.** Cyclic pressure modulates endothelial permeability and endothelial junctional proteins. Endothelium (in press)
96. **Gerritsen, M.E.** Peale, F. and Wu, T. Gene Expression Profiling in silico: Relative Expression of Candidate Angiogenesis Associated Genes in Renal Cell Carcinomas. Exp. Nephrology 10:114-119, 2002.
97. Zlot, C., Ingle, G., Hongo, J., Yang, S., Peale, F.V. and **Gerritsen M.E.** Stanniocalcin 1, a secreted glycoprotein focally expressed at sites of physiological and pathological angiogenesis, is an inhibitor of hepatocyte growth factor induced endothelial migration (J. Biol. Chem. accepted for publication)
98. Filvaroff, E., Guillet, S., Zlot, C., Bao, M., Ingle, G., Steinmetz, H., Hoeffel, J., Bunting S., Ross, J., Carano, R.A.D., Powell-Braxton, L., Wagner, G.F., **Gerritsen, M.E.** and French, DM., Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice. Endocrinology 143:3681-90, 2002
99. Tejada, M., Pelletier, N. and **Gerritsen, M.E.**, A novel neuropeptide is a modulator of angiogenesis and permeability in vitro and in vivo (in preparation)
100. Yang, S. Toy, K., Ingle, G., Williams, PM, Fuh, G, Li, B, de Vos, A, and **Gerritsen, M.E.**, Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler. Thromb. Vasc. Biol. 22:1797-803, 2002
101. Paoni, N.F., Peale, F., Wang, F., Errett-Baroncini, C., Steinmetz, H., Toy, K., Bai, W., Williams, P.M., Bunting, S., **Gerritsen, M.E.**, and Powell-Braxton, L. Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiological Genomics 11:262-72. 2002
102. Yang, S. Lee, B.J., DeVaux, B. and **Gerritsen M.E.** 19C11, an endothelial specific antibody, selectively recognizes an antigen on proliferating endothelial cells (in preparation).
103. Shin, H., Smith, M.L., Toy, K., Williams, P.M. and **Gerritsen, M.E.**, VEGFC mediates cyclic pressure induced endothelial cell proliferation. Physiological Genomics 11:245-51, 2002
104. Chang, T-L, **Gerritsen, M.E.**, Hill, M. Kubes, P. and Perry, M., Microcirculation down under. Trends in Pharmacological Science 23:106-8, 2002.

105. **Gerritsen, M.E.**, Soriano, R, Yang, S, Zlot, C, Ingle, G, Toy, K and Williams, P.M.. Branching Out: A molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. *Microcirculation* 10: 63-81, 2003
106. Eggington, S. and **Gerritsen, M.** Lumen formation: in vivo versus in vitro observations. *Microcirculation* 10:45-61, 2003.
108. Yang, RB, Ng, CKD, Wasserman, SM, Komuves, LG, **Gerritsen, ME** and Topper, JN. A novel IL-17 receptor like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. *J. Biol. Chem.* 278:33232-8,2003
109. **Gerritsen, ME**, Tomlinson, JE, Zlot, C, Ziman, M, Hwang, S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. *Br. J. Pharmacol* 140:595-610, 2003
110. Zlot, C. Ingle, G, Hong, J. Yang, S, Shen, Z, Schwall, R, Paoni, N, Wang, F, Peale, FV jr, **Gerritsen, ME.** Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. *J Biol Chem.* 278: 47654-9.
111. Shin, HY, Bizios, R, **Gerritsen, ME.** Cyclic pressure modulates endothelial barrier function. *Endothelium* 10:179-187, 2003.
112. Gerritsen, M.E. Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to vascular disease. *Microcirculation* (in press)
113. Gerritsen, M.E. HGF and VEGF-Dynamic Duo. *Circulation* (in press)

### **Book chapters**

1. **Gerritsen, M.E.** and Lederis, K. Effects of urotensin I on isolated blood vessels. *Proc. West. Pharmacol. Soc.* 19:461-465, 1976.
2. **Gerritsen, M.E.** Mathison, R. and Lederis, K. Urotensin I induced relaxation and intracellular cAMP. *Proc. West. Pharmacol. Soc.* 20:133-137, 1977
3. **Gerritsen, M.E.** and Lederis, K. Effects of urotensin I on the isolated rat tail artery: possible mediation of the relaxation response by cAMP. *Proc. West. Pharmacol. Soc.* 21:250-253, 1978.



4. Parks, T.P., **Gerritsen, M.E.**, Printz, M.P. and Lederis K. Prostaglandin production in the rat tail artery and vein. *Proc. West. Pharmacol. Soc.* 21:241-244, 1978.
5. **Gerritsen, M.E.** Vascular actions of urotensin I. Doctoral Dissertation. University of Calgary, 1978.
- 6.. **Gerritsen, M.E.**, Weinstein, B.I. and Southren, A.L. Arachidonate metabolism and prostaglandin release from human trabecular meshwork cells. In: Prostaglandins, Leukotrienes and Lipoxins. J. Martin Bailey, Ed. Plenum Press 185-192, 1985.
7. **Gerritsen, M.E.**, Milici, A.J. and Carley, W.W. Microvascular endothelial cells: isolation, identification and culture. Advances in Cell Culture 6:35-37, 1988.
8. **Gerritsen, M.E.** and Medow, M.S. A role for extracellular sodium in the regulation of microvascular endothelial prostaglandin production. In Microcirculation, an update. (Tsuchiya, M., Asano, M., Mishima, Y. and Oda, M. eds) 735-738, 1988.
9. **Gerritsen, M.E.** and Mannix, R.J. G-proteins and phospholipase activation in endothelial cells. Adv. Exp. Med. Biol. Phospholipase A<sub>2</sub>, role and function in Inflammation. P.Y.K. Wong and E. Dennis, Eds. Vol 275: 115-124, 1990.
10. Szczepanski, A., Carley, W.W., Marshall, P. Mullins, L., Rayan, G. and **Gerritsen, M.E.** Isolation and characterization of synovial endothelial cells from patients with rheumatoid arthritis. Eicosanoid production. In: Advances in Rheumatology and Inflammation. 2. Leukotrienes and the vascular phenomena of Inflammation related to rheumatoid arthritis. (EULAR, Babel). R. Muller Peddinghaus, ed 119-128, 1992.
11. Capetandes, A. and **Gerritsen, M.E.** Heterogeneity in retinal microvascular endothelial cell growth control by pericytes. In Biology of the Ocular Microcirculation ( Weinreb, R.N. and L.A. Wheeler, eds. Elsevier) 81-90, 1992.
12. Kalfa, T.A. **Gerritsen, M.E.**, Tsilibary, E.C. Altered proliferation of retinal microvascular cells in response to non-enzymatic glycosylated matrix proteins. In Angiogenesis: Molecular Biology, Clinical Aspects, M.E. Marangoudakis (ed). Plenum Publishing Company, London. pp 101-108.
13. **Gerritsen, M.E.** Physiological Functions of Endothelium. Chapter 1 In Vascular Medicine (2 ed). ( J Loscalzo, MA Creager and VJ Dzau eds. Little Brown and Company, Boston MA USA) pp 3-39.
14. Silverman E.S., **Gerritsen, M.E.** and Collins T. Metabolic Functions of the Pulmonary Endothelium. Chapter 43 in THE LUNG: Scientific Foundations (Second Edition) RG Crystal, JB West, E Weibel and P Barnes ed . Lippincott-Raven, Philadelphia. pp 629-651

15. **Gerritsen, M.E.** Targeting Transcriptional Regulation of Adhesion Protein Expression: A new approach to anti-adhesion therapy. In Collins, T. Transcriptional Regulation of Adhesion Protein Expression (in press)
16. **Gerritsen, M.E.** Flavonoids: Inhibitors of cytokine induced gene expression. In: Flavonoids in the Living System, Adv Exp Med Biol.439. Manthey and Buslig eds. Plenum Press, New York, 1998. pp 183-190.
17. Schwartz, EA, Bizios, R, and **Gerritsen, M.E.** Effects of sustained hydrostatic pressure on the expression of endothelial cell-leukocyte adhesion molecules. In: Pulmonary Edema, Wier, EK and Reeves, JT (eds) Future Publishing Co., Armonk NY 1998. pp 195-203.
18. Schwartz, EA, Bizios, R and **Gerritsen, M.E.** Effects of hydrostatic pressure on endothelial cells. In: Physical Forces and Vascular Cells. PE. Lelkes, Editor. Harwood Academic Publishers Amsterdam 1999 pp275-290.
19. Collins, TC and **Gerritsen, M.E.** Preface: transcriptional control of cell adhesion molecules. In: Leukocyte recruitment, endothelial cell adhesion molecules and transcriptional control. Insights for drug discovery. T Collins, Editor Kluwer Academic Publishers, Boston, 2000
20. Parks, TP and **Gerritsen, M.E.** Regulation of Intercellular Adhesion Molecule (ICAM) Gene Expression. In: Leukocyte recruitment, endothelial cell adhesion molecules and transcriptional control. Insights for drug discovery. T Collins, Editor Kluwer Academic Publishers, Boston, 2000. pp 109-174.
21. **Gerritsen, M.E.** . Therapeutic regulation of leukocyte adhesion molecule expression. . In: Leukocyte recruitment, endothelial cell adhesion molecules and transcriptional control. Insights for drug discovery. T Collins, Editor Kluwer Academic Publishers, Boston, 2000. pp 263-303.
22. **Gerritsen, ME.** Endothelial Heterogeneity. In. Encyclopedia of the Microvasculature Academic Press, (in press, 2004)
23. **Gerritsen, ME.** Gene profiling techniques and their application in cardiovascular disease. In Cardiovascular Genomics, MK Raizada ed. Human Press. (in press)
24. **Gerritsen, ME.** Endothelial phenotypes: genomic diversity. In. Endothelial phenotypes in health and disease. W. Aird ed. (in preparation).
25. **Gerritsen, ME.** Angiogenesis. In: Handbook of Physiology (in press)
26. **Gerritsen, ME** and Wagner, G. Stanniocalcin-No longer just a fish tale. In: Vitamins and Hormones, Elsevier Press. (in press)
27. **Gerritsen, ME.** Therapeutic Angiogenesis. Encyclopedia of Molecular Medicine (in press)

28. Gerritsen, ME and Parsons, R Masdevallias, gems of the orchid world. Timber Press (in press)

**Patents: Issued or Published.**

(note that there I have over 900 patent applications pending; for the sake of brevity a few representative ones are listed)

WO0104311 Secreted and Transmembrane Polypeptides and Nucleic Acids

WO9914234 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION

WO0030628 METHOD OF INHIBITING ANGIOGENESIS

WO0103720 CARDIOVASCULAR USES FOR GLITTER/GITR

WO0125433 ANGIOGENESIS MODULATING GENES

WO0032776 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

WO0053756 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

WO0073454 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

WO0053757 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION

WO0073445 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION

WO0077037 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

WO0116318 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

WO0140466 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME